Lucid Diagnostics, Inc.
(NASDAQ : LUCD)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Medical Specialties
symbolcompany%chnglast%shortavg$volume
TMOThermo Fisher Scientific, Inc. -0.81%538.891.0%$620.13m
DHRDanaher Corp. -0.07%253.350.7%$585.62m
MDTMedtronic Plc -0.03%89.720.6%$582.79m
ABTAbbott Laboratories -0.18%108.460.8%$575.28m
ISRGIntuitive Surgical, Inc. 0.42%201.560.8%$422.82m
BSXBoston Scientific Corp. 0.13%37.321.0%$329.71m
ALGNAlign Technology, Inc. 2.25%242.006.4%$284.05m
BDXBecton, Dickinson & Co. 0.65%248.141.0%$274.60m
SYKStryker Corp. -0.10%198.741.3%$261.44m
EWEdwards Lifesciences Corp. 0.54%95.600.4%$254.65m
IDXXIDEXX Laboratories, Inc. 0.33%351.893.8%$222.27m
BAXBaxter International, Inc. 0.22%64.371.8%$197.45m
AAgilent Technologies, Inc. -0.85%117.761.7%$196.76m
DXCMDexCom, Inc. 2.31%76.251.9%$179.31m
SWAVShockwave Medical, Inc. 2.16%195.300.0%$169.73m

Company Profile

Lucid Diagnostics, Inc. develops medical testing devices. It is a commercial-stage medical diagnostics technology company which focuses on gastroesophageal reflux disease (GERD), acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma (EAC). The firm's products include EsoCheck is a cell collection device that is designed to collect cells of a targeted region of the esophagus without the need for endoscopy and EsoGuard is a laboratory developed test which analyzes methylated biomarkers. The company was founded on May 8, 2018 and is headquartered in New York, NY.